DAWN (Day One Biopharmaceuticals) ROC %: -363.76% (As of Dec. 2025)

What is Day One Biopharmaceuticals ROC %?

Day One Biopharmaceuticals DAWN 12 ROC % is -363.76% as of Dec. 2025. GuruFocus rates DAWN with a GF Score™ of 12/100. The stock has 5 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Day One Biopharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Dec. 2025 was -363.76%.

As of today (2026-06-25), Day One Biopharmaceuticals's WACC % is 10.48%. Day One Biopharmaceuticals's ROC % is -455.40% (calculated using TTM income statement data). Day One Biopharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Day One Biopharmaceuticals (NAS:DAWN) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Day One Biopharmaceuticals's WACC % is 10.48%. Day One Biopharmaceuticals's ROC % is -455.40% (calculated using TTM income statement data). Day One Biopharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Day One Biopharmaceuticals ROC % Related Terms

Day One Biopharmaceuticals ROC % Historical Data

* Premium members only.

The historical data trend for Day One Biopharmaceuticals's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Day One Biopharmaceuticals ROC % Chart

Day One Biopharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROC %

Get a 7-Day Free Trial

-9,231.35

-11,599.61

-10,316.10

-1,705.28

-513.74

Day One Biopharmaceuticals Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
ROC %	Get a 7-Day Free Trial															-1,064.39	-611.49	-472.53	-332.07	-363.76

12GF Score

Day One Biopharmaceuticals Inc DAWN

ROC % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Day One Biopharmaceuticals ROC % Calculation

Day One Biopharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

	ROC % (A: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2024 )	+	Invested Capital (A: Dec. 2025 ))	/ count )
=	-127.75 * ( 1 - 1.81% )	/	( (23.259	+	25.574)	/ 2 )
=	-125.437725	/	24.4165
=	-513.74 %

where

	Invested Capital		(A: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	582.788	-	70.65	-	( 531.72	-	max(0, 73.451	-	562.33	+	531.72	))
=	23.259

	Invested Capital		(A: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	507.827	-	57.676	-	( 441.113	-	max(0, 60.522	-	485.099	+	441.113	))
=	25.574

Day One Biopharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2025 is calculated as:

	ROC % (Q: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2025 )	+	Invested Capital (Q: Dec. 2025 ))	/ count )
=	-109.832 * ( 1 - 8.5% )	/	( (29.68	+	25.574)	/ 2 )
=	-100.49628	/	27.627
=	-363.76 %

where

	Invested Capital		(Q: Sep. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	513.78	-	50.595	-	( 451.58	-	max(0, 56.466	-	489.971	+	451.58	))
=	29.68

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	507.827	-	57.676	-	( 441.113	-	max(0, 60.522	-	485.099	+	441.113	))
=	25.574

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data. The tax rate is limited to between 0% and 100%.

Frequently Asked Questions Learn more about ROC % →

What does a ROC % of -363.76% mean?

Day One Biopharmaceuticals (DAWN) has a ROC % of -363.76% as of Dec. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Day One Biopharmaceuticals and its competitors.

Is Day One Biopharmaceuticals' ROC % too high?

Day One Biopharmaceuticals' current ROC % is -363.76%. Overall, Day One Biopharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.

How does Day One Biopharmaceuticals' ROC % compare to TYRA and DFTX?

Day One Biopharmaceuticals' ROC % of -363.76% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROC % for a Biotechnology company?

A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROC % mean?

A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Day One Biopharmaceuticals and its competitors. Day One Biopharmaceuticals's current ROC % is -363.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Day One Biopharmaceuticals stock overvalued right now?

Day One Biopharmaceuticals (DAWN) has a current ROC % of -363.76%. The current ROC % is -363.76%. Day One Biopharmaceuticals' overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROC % calculated?

ROC % is calculated from a company's financial statements. For Day One Biopharmaceuticals (DAWN), the current ROC % is -363.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Day One Biopharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies TYRA DFTX MLYS ADPT SRPT ZYME RARE AUPH OCUL TRVI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ASX:CSL ALNY ONC XKRX:068270 INSM

Address 1800 Sierra Point Parkway, Suite 200, Brisbane, CA, USA, 94005

Website https://www.dayonebio.com

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.

12GF Score

Get the complete analysis for DAWN

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.53

Price

View DAWN Analysis

See ROC % data for all stocks →